Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
AJNR Am J Neuroradiol ; 42(3): 441-447, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33414227

RESUMO

BACKGROUND AND PURPOSE: Studies consistently report lower ADC values in isocitrate dehydrogenase (IDH) wild-type gliomas than in IDH mutant tumors, but their methods and thresholds vary. This research aimed to compare volumetric and regional ADC measurement techniques for glioma genotyping, with a focus on IDH status prediction. MATERIALS AND METHODS: Treatment-naïve World Health Organization grade II and III gliomas were analyzed by 3 neuroradiologist readers blinded to tissue results. ADC minimum and mean ROIs were defined in tumor and in normal-appearing white matter to calculate normalized values. T2-weighted tumor VOIs were registered to ADC maps with histogram parameters (mean, 2nd and 5th percentiles) extracted. Nonparametric testing (eta2 and ANOVA) was performed to identify associations between ADC metrics and glioma genotypes. Logistic regression was used to probe the ability of VOI and ROI metrics to predict IDH status. RESULTS: The study included 283 patients with 79 IDH wild-type and 204 IDH mutant gliomas. Across the study population, IDH status was most accurately predicted by ROI mean normalized ADC and VOI mean normalized ADC, with areas under the curve of 0.83 and 0.82, respectively. The results for ROI-based genotyping of nonenhancing and solid-patchy enhancing gliomas were comparable with volumetric parameters (area under the curve = 0.81-0.84). In rim-enhancing, centrally necrotic tumors (n = 23), only volumetric measurements were predictive (0.90). CONCLUSIONS: Regional normalized mean ADC measurements are noninferior to volumetric segmentation for defining solid glioma IDH status. Partially necrotic, rim-enhancing tumors are unsuitable for ROI assessment and may benefit from volumetric ADC quantification.


Assuntos
Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/genética , Técnicas de Genotipagem , Glioma/diagnóstico por imagem , Glioma/genética , Adulto , Idoso , Neoplasias Encefálicas/patologia , Imagem de Difusão por Ressonância Magnética/métodos , Feminino , Genótipo , Glioma/patologia , Humanos , Isocitrato Desidrogenase/genética , Masculino , Pessoa de Meia-Idade , Mutação , Estudos Retrospectivos , Organização Mundial da Saúde
3.
Nat Commun ; 11(1): 1160, 2020 03 03.
Artigo em Inglês | MEDLINE | ID: mdl-32127545

RESUMO

Could nose-to-brain pathways mediate the effects of peptides such as oxytocin (OT) on brain physiology when delivered intranasally? We address this question by contrasting two methods of intranasal administration (a standard nasal spray, and a nebulizer expected to improve OT deposition in nasal areas putatively involved in direct nose-to-brain transport) to intravenous administration in terms of effects on regional cerebral blood flow during two hours post-dosing. We demonstrate that OT-induced decreases in amygdala perfusion, a key hub of the OT central circuitry, are explained entirely by OT increases in systemic circulation following both intranasal and intravenous OT administration. Yet we also provide robust evidence confirming the validity of the intranasal route to target specific brain regions. Our work has important translational implications and demonstrates the need to carefully consider the method of administration in our efforts to engage specific central oxytocinergic targets for the treatment of neuropsychiatric disorders.


Assuntos
Encéfalo/efeitos dos fármacos , Circulação Cerebrovascular/efeitos dos fármacos , Ocitocina/administração & dosagem , Administração Intranasal , Administração Intravenosa , Adulto , Tonsila do Cerebelo/irrigação sanguínea , Encéfalo/irrigação sanguínea , Método Duplo-Cego , Frequência Cardíaca/efeitos dos fármacos , Humanos , Imageamento por Ressonância Magnética , Masculino , Nebulizadores e Vaporizadores , Ocitocina/sangue , Ocitocina/farmacocinética , Placebos , Adulto Jovem
4.
Parasitology ; 138(12): 1480-7, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21554841

RESUMO

Trypanosoma brucei gambiense sleeping sickness follows a long asymptomatic phase and persists in ancient foci from which epidemic clinical disease arises. A putative focus of T. b. gambiense infections has been identified, initially in mothers and young children, on the Lake Albert shoreline of Western Uganda leading to mass screening of 6207 individuals in September 2008. T. b. gambiense infections were identified by Card Agglutination Test for Trypanosomiasis (CATT) and sub-species-specific PCR although parasitological methods failed to confirm any patent trypanosome infections. In April 2009, CATT positives were re-visited; diagnosis of individuals by CATT and PCR was unstable over the two time points and parasites remained undetected, even using mini Anion Exchange Centrifugation Technique (mAECT). These observations suggest the possibility of a silent focus of disease, where all infected individuals are in a latent stage, and highlight our limited understanding of the local natural history and disease progression of T. b. gambiense in children and adults.


Assuntos
Trypanosoma brucei gambiense/isolamento & purificação , Tripanossomíase Africana/diagnóstico , Tripanossomíase Africana/epidemiologia , Adulto , Testes de Aglutinação , Doenças Assintomáticas , Criança , DNA de Protozoário/isolamento & purificação , Coleta de Dados , Feminino , Seguimentos , Humanos , Lagos , Programas de Rastreamento , Reação em Cadeia da Polimerase , Tripanossomíase Africana/parasitologia , Uganda/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...